bioAffinity Technologies Presents at Cleveland Clinic Lung Cancer Symposium
25 Aprile 2023 - 2:00PM
Business Wire
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a
biotechnology company focused on the need for noninvasive, accurate
tests for the detection of early-stage cancer, will present at the
Cleveland Clinic’s invitation-only Advances in Early Lung Cancer
Detection annual symposium in Cleveland, Ohio, on April 27,
2023.
The presentation by Vivienne I. Rebel, MD, PhD, bioAffinity
Technologies Executive Vice President and Chief Science and Medical
Officer, will focus on advancements in CyPath® Lung, the Company’s
noninvasive test for detection of early-stage lung cancer. CyPath®
Lung uses flow cytometry and artificial intelligence to analyze the
lung microenvironment to identify cell populations that accurately
predict cancer in patients at high risk for lung cancer.
The fourth annual Advances in Early Lung Cancer Detection
symposium brings together global leaders in the field of lung
cancer, including physicians, advocates and industry, to accelerate
the development and implementation of new technologies and methods
to find lung cancer at the earliest stages when it is most
treatable. This is bioAffinity Technologies’ fourth invitation to
present before symposium attendees.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. addresses the need for
noninvasive diagnosis of early-stage cancer and diseases of the
lung and targeted cancer treatment. The Company’s first product,
CyPath® Lung, is a noninvasive test that has shown high sensitivity
and specificity for the detection of early-stage lung cancer.
CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by
Precision Pathology Services. OncoSelect® Therapeutics, LLC, a
subsidiary of bioAffinity Technologies, is advancing its
discoveries shown in vitro to kill cancer cells without harm to
normal cells. Research and optimization of the Company’s platform
technologies are conducted in its laboratories at The University of
Texas at San Antonio. For more information, visit
www.bioaffinitytech.com and follow us on LinkedIn and Twitter.
About the Cleveland Clinic
The Cleveland Clinic is a nonprofit multispecialty academic
medical center that integrates clinical and hospital care with
research and education. Founded in 1921 to provide outstanding
patient care based upon cooperation, compassion and innovation, the
Cleveland Clinic has pioneered many medical breakthroughs and is
consistently named one of the nation’s best hospitals.
Forward-Looking Statements
This press release contains forward-looking statements,
including statements regarding the anticipated use of proceeds from
the Company’s offering of common shares. Forward-looking statements
can be identified by words such as “believes,” “expects,”
“estimates,” “intends,” “may,” “plans,” “will” and similar
expressions, or the negative of these words. Such forward-looking
statements are based on facts and conditions as they exist at the
time such statements are made and predictions as to future facts
and conditions. Readers of this press release are cautioned not to
place undue reliance on any forward-looking statements. The Company
does not undertake any obligation to update any forward-looking
statement relating to matters discussed in this press release,
except as may be required by applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230425005119/en/
bioAffinity Technologies Julie Anne Overton Director of
Communications jao@bioaffinitytech.com
LHA Investor Relations Tirth T. Patel tpatel@lhai.com
Grafico Azioni bioAffinity Technologies (NASDAQ:BIAFW)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni bioAffinity Technologies (NASDAQ:BIAFW)
Storico
Da Giu 2023 a Giu 2024